anzemet
Pharmaranks rates Anzemet 3.6/5 for recall safety — an independent score from its FDA recall history and its manufacturer's record. Anzemet (Dolasetron Mesylate) is a medication used to treat Postoperative Nausea and Vomiting.
Dolasetron Mesylate · by Validus Pharms
Based on 1 source · Recall-safety score from FDA recall history — this product's own recalls and its manufacturer's record. Not an efficacy or quality rating. methodology →
Key facts
- Active ingredient
- Dolasetron Mesylate
- Form
- Injectable, Tablet
- Strength
- Dolasetron Mesylate 100MG/5ML (20MG/ML) · Dolasetron Mesylate 12.5MG/0.625ML (20MG/ML) · Dolasetron Mesylate 500MG/25ML (20MG/ML)
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- May treat
- postoperative nausea and vomiting
- Manufacturer
- Validus Pharms
- FDA application
- NDA020624
- Availability
- Discontinued (per FDA)
May treat (source: NIH RxClass)
Dosage forms
Injectable and Tablet
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Anzemet treat?
- Anzemet (Dolasetron Mesylate) may be used to treat postoperative nausea and vomiting, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- How is Anzemet rated?
- pharmaranks gives Anzemet a composite score of 3.6 out of 5, currently based on 1 weighted source (FDA regulatory recall-safety data weighted highest). See our methodology at /how-we-rate.
- Is there a coupon or discount for Anzemet?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Anzemet. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Anzemet?
- Anzemet is marketed by Validus Pharms. You can see Validus Pharms's full profile, rating, and other products on pharmaranks.
- Is Anzemet a brand-name or generic drug?
- Anzemet is a brand-name product with the active ingredient Dolasetron Mesylate.
- Is Anzemet available over the counter?
- No. Anzemet is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Anzemet come in?
- Anzemet is currently marketed as injectable and tablet, per the FDA's National Drug Code Directory.
- Is Anzemet FDA-registered?
- Anzemet is on record with the U.S. FDA under application number NDA020624. You can verify this on its official FDA label.
- Has Anzemet been recalled by the FDA?
- Anzemet has no FDA recalls recorded under its own application in the openFDA enforcement database. Its recall-safety score reflects its manufacturer's overall recall record. This is general reference, not medical advice — check the FDA recall database for the latest alerts.
- Is Anzemet safe?
- There's no single safe-or-not verdict. pharmaranks gives Anzemet a recall-safety score of 72/100, based on its FDA recall history (no recalls under its own FDA application) — not an efficacy or side-effect rating. Review its FDA-label side effects and warnings before use, and always consult a licensed professional.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about DOLASETRON MESYLATE
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 162 reports naming DOLASETRON MESYLATE — the active ingredient in Anzemet, and the FDA flagged 93% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- white blood cell count decreased28 reports
- myelosuppression27 reports
- platelet count decreased22 reports
- neutrophil count decreased17 reports
- vomiting17 reports
- nausea16 reports
- hypokalaemia13 reports
- asthenia12 reports
Read these as a signal, not a rate. A report does not mean DOLASETRON MESYLATE caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 25, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
Compare Anzemet head-to-head
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
anzemet
72/100